Besides, elevated level of IL-5 and IL-15 in rEOC, it is very interesting to find the elevated level of IL-2 in their sera as IL-2 has promising therapeutic potential, a phase II clinical trial has shown its therapeutic benefits in platinum-resistant ovarian cancer patients [40]. This evidence concerns the gene IL5 and ovarian carcinoma.